Green light for Immunovaccine’s combination trial
December 2017
SHARING OPTIONS:

HALIFAX, Nova Scotia—In November, Immunovaccine Inc. reported that it had received Sunnybrook Research Institute regulatory clearance from Health Canada to start recruiting for a Phase 2 clinical study of a triple-combination immunotherapy in patients with measurable or recurrent diffuse large B cell lymphoma. The study will assess the safety and efficacy of DPX-Survivac, Immunovaccine’s lead product candidate, in combination with Merck’s pembrolizumab and low-dose cyclophosphamide.
 
Frederic Ors, CEO of Immunovaccine, said that “Despite promising results observed in the treatment of DLBCL with cutting-edge monotherapies like checkpoint inhibitors, a significant number of patients still do not respond to treatment … Through complementary mechanisms of action, we believe the combination of DPX-Survivac and pembrolizumab could amplify T cell production and infiltration to help realize the desired immune response in a broader range of patients with this type of cancer.”

Back
 
CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.